Ameliorative potential of omega 3 fatty acids and HMG-CoA reductase inhibitors on experimentally-induced non-alcoholic steatohepatitis

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 96, Issue , 2015, Pages 1-9

  Kabel, Ahmed M ^a,b   Abd Elmaaboud, Maaly A ^b   Albarraq, Ahmed A ^a  

^a TAIF UNIVERSITY   (Saudi Arabia)

^b TANTA UNIVERSITY   (Egypt)

Author keywords

Atorvastatin; Cholesterol; Fish oil; NASH

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; FISH OIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 6; MALONALDEHYDE; OMEGA 3 FATTY ACID; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; LIPID; SUCROSE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID ANALYSIS; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; TISSUE SECTION; TRIACYLGLYCEROL BLOOD LEVEL; ADVERSE EFFECTS; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECTS; INFLAMMATION; LIPID DIET; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; WISTAR RAT;

RATTUS;

ANIMALS; ATORVASTATIN CALCIUM; BODY WEIGHT; CYTOKINES; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FATTY ACIDS, OMEGA-3; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; INSULIN RESISTANCE; LIPIDS; LIVER; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; RATS, WISTAR; SUCROSE;

EID: 84927069414     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2014.12.003     Document Type: Article

References (52)

1. Clark J.M. The epidemiology of nonalcoholic fatty liver disease in adults. J. Clin. Gastroenterol. 2006, 40:5-10.
2. Angulo P. NAFLD, obesity, and bariatric surgery. Gastroenterology 2006, 130:1848-1852.
3. Abdelmalek M.F., Diehl A.M. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med. Clin. N. Am. 2007, 91:1125-1149.
4. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 2010, 363:1341-1350.
5. Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010, 52:1836-1846.
6. Neuschwander-Tetri B.A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010, 52:774-788.
7. Bookman I.D., Pham J., Guindi M., et al. Distinguishing nonalcoholic steatohepatitis from fatty liver: serum-free fatty acids, insulin resistance, and serum lipoproteins. Liver Int. 2006, 26:566-571.
8. Koruk M., Savas M.C., Yilmaz O., et al. Serum lipids, lipoproteins and apolipoproteins levels in patients with nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2003, 37:177-182.
9. Fon Tacer K., Rozman D. Nonalcoholic fatty liver disease: focus on lipoprotein and lipid deregulation. J. Lipids 2011, 783976.
10. Kabel A.M. Statins: a new hope for cancer therapy. J. Cancer Res. Treat. 2013, 1:36-38.
11. Lewis A., Lookinland S., Beckstrand R.L., et al. Treatment of hypertriglyceridemia with omega-3 fatty acids: a systematic review. J. Am Acad. Nurse Pract. 2004, 16:384-395.
12. Tull S.P., Yates C.M., Maskrey B.H., et al. Omega-3 Fatty acids and inflammation: novel interactions reveal a new step in neutrophil recruitment. PLoS Biol. 2009, 7:e1000177.
13. Barter P., Ginsberg H.N. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am. J. Cardiol. 2008, 102:1040-1045.
14. Nambi V., Ballantyne C.M. Combination therapy with statins and omega-3 fatty acids. Am. J. Cardiol. 2006, 98:34i-38i.
15. Zou Y., Li J., Lu C., et al. High-fat emulsion-induced rat model of nonalcoholic steatohepatitis. Life Sci. 2006, 79:1100-1107.
16. Matafome P., Nunes E., Louro T., et al. A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia. Naunyn Schmiedebergs Arch. Pharmacol. 2009, 379:241-251.
17. Gopumadhavan S., Rafiq M., Azeemuddin M., et al. Ameliorative effect of Partysmart in rat model of alcoholic liver disease. Indian J. Exp. Biol. 2008, 46:132-137.
18. Henry R.J., Chiamori N., Golub O.J., et al. Revised spectrophotometric methods for the determination of glutamic-oxalacetic transaminase, glutamic-pyruvic transaminase, and lactic acid dehydrogenase. Am. J. Clin Pathol. 1960, 34:381-398.
19. Roeschlau P., Bernt E., Gruber W. Enzymatic determination of total cholesterol in serum. Z. Klin. Chem. Klin. Biochem. 1974, 12:226.
20. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18:499-502.
21. Fossati P., Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin. Chem. 1982, 28:2077-2080.
22. Otsuji S., Shibata H., Umeda M. Turbidimetric immunoassay of serum C-reactive protein. Clin. Chem. 1982, 28:2121-2124.
23. Trinder P. Determination of blood glucose using 4-amino phenazone as oxygen acceptor. J. Clin. Pathol. 1969, 22:246.
24. Katz A., Nambi S.S., Mather K., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab. 2000, 85:2402-2410.
25. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 37:911-917.
26. Uchiyama M., Mihara M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal. Biochem. 1978, 86:271-278.
27. Doumas B.T. Standards for total serum protein assays--a collaborative study. Clin. Chem. 1975, 21:1159-1166.
28. Staunton M.J., Gaffney E.F. Tumor type is adeterminant of susceptibility to apoptosis. Am. J. Clin. Pathol. 1995, 103:300-307.
29. Yunianingtias D., Volker D. Nutritional aspects of non-alcoholic steatohepatitis treatment. Nutr. Diet. 2006, 63:79-90.
30. Nathan D.M. Rosiglitazone and cardiotoxicity--weighing the evidence. N. Engl. J. Med. 2007, 357:64-66.
31. Dowman J.K., Tomlinson J.W., Newsome P.N. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010, 103:71-83.
32. Tandra S., Yeh M.M., Brunt E.M., et al. Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. J. Hepatol. 2011, 55:654-659.
33. Brunt E.M., Kleiner D.E., Wilson L.A., et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009, 49:809-820.
34. Olleros M.L., Martin M.L., Vesin D., et al. Fat diet and alcohol-induced steatohepatitis after LPS challenge in mice: role of bioactive TNF and Th1 type cytokines. Cytokine 2008, 44:118-125.
35. Achyut B.R., Yang L. Transforming growth factor-beta in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology 2011, 141:1167-1178.
36. S. Dooley, P. ten Dijke, TGF-beta in progression of liver disease, Cell Tissue Res. 347 (2012) 245-256.
37. Yang L., Roh Y.S., Song J., et al. Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology 2014, 59:483-495.
38. Lin H.M., Lee J.H., Yadav H., et al. Transforming growth factor-beta/Smad3 signaling regulates insulin gene transcription and pancreatic islet beta-cell function. J. Biol. Chem. 2009, 284:12246-12257.
39. Yadav H., Quijano C., Kamaraju A.K., et al. Protection from obesity and diabetes by blockade of TGF-beta/Smad3 signaling. Cell Metab. 2011, 14:67-79.
40. Tan C.K., Leuenberger N., Tan M.J., et al. Smad3 deficiency in mice protects against insulin resistance and obesity induced by a high-fat diet. Diabetes 2011, 60:464-476.
41. Roglans N., Sanguino E., Peris C., et al. Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. J. Pharmacol. Exp. Ther. 2002, 302:232-239.
42. Tontonoz P., Mangelsdorf D.J. Liver X receptor signaling pathways in cardiovascular disease. Mol. Endocrinol. 2003, 17:985-993.
43. Khaodhiar L., Ling P.R., Blackburn G.L., et al. Serum levels of interleukin-6 and C-reactive protein correlate with body mass index across the broad range of obesity. J. Parenter. Enter. Nutr. 2004, 28:410-415.
44. Fontana L., Eagon J.C., Trujillo M.E., et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007, 56:1010-1013.
45. van der Poorten D., Milner K.L., Hui J., et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008, 48:449-457.
46. Van Rooyen D.M., Farrell G.C. SREBP-2: A link between insulin resistance, hepatic cholesterol, and inflammation in NASH. J. Gastroenterol. Hepatol. 2011, 26:789-792.
47. Koek G.H., Liedorp P.R., Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin. Chim. Acta 2011, 412:1297-1305.
48. Kalupahana N.S., Claycombe K.J., Moustaid-Moussa N. (n-3) Fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights. Adv. Nutr. 2011, 2:304-316.
49. Svegliati-Baroni G., Candelaresi C., Saccomanno S., et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am. J. Pathol. 2006, 169:846-860.
50. Micallef M.A., Garg M.L. Beyond blood lipids: phytosterols, statins and omega-3 polyunsaturated fatty acid therapy for hyperlipidemia. J. Nutr. Biochem. 2009, 20:927-939.
51. Nestel P.J. Fish oil and cardiovascular disease: lipids and arterial function. Am. J. Clin. Nutr. 2000, 71:228S-231S.
52. Van Linthout S., Foryst-Ludwig A., Spillmann F., et al. Impact of HDL on adipose tissue metabolism and adiponectin expression. Atherosclerosis 2010, 210:438-444.